Development of replication-competent adenovirus for bladder cancer by controlling adenovirus E1a and E4 gene expression with the survivin promoter

9Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Survivin is a member of the inhibitors of apoptosis protein family. Here, we examined survivin expression and confirmed abundant survivin expression in bladder cancer cells. This expression pattern indicated that the transcriptional regulatory elements that control survivin expression could be utilized to discriminate cancer from normal cells. We therefore generated a novel adenovirus termed Ad5/35E1apsurvivinE4 with the following characteristics: 1) E1A and E4 protein expression was dependent on survivin promoter activity; 2) the green fluorescence protein gene was inserted into the genome under the control of the CMV promoter; 3) most of the E3 sequences were deleted, but the construct was still capable of expressing the adenovirus death protein with potent cytotoxic effects; and 4) the fiber knob was from serotype 35 adenovirus. As expected from the abundant survivin expression observed in bladder cancer cells, Ad5/35E1apsurvivinE4 replicated better in cancer cells than in normal cells by a factor of 106 to 102. Likewise, Ad5/35E1apsurvivinE4 exerted greater cytotoxic effects on all bladder cancer cell lines tested. Importantly, Ad5/35E1apsurvivinE4 inhibited the growth of Ku7-Luc orthotopic xenografts in nude mice. Taken together, Ad5/35E1apsurvivinE4 indicates that the survivin promoter may be utilized for the development of a replication-competent adenovirus to target bladder cancers.

References Powered by Scopus

Cancer statistics, 2013

11919Citations
N/AReaders
Get full text

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

3105Citations
N/AReaders
Get full text

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials

2378Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Trial Watch—Oncolytic viruses and cancer therapy

98Citations
N/AReaders
Get full text

Targeted therapies in bladder cancer: An overview of in vivo research

74Citations
N/AReaders
Get full text

A classical PKA inhibitor increases the oncolytic effect of M1 virus via activation of exchange protein directly activated by cAMP 1

24Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Seo, H. K., Seo, J. B., Nam, J. K., Jeong, K. C., Shin, S. P., Kim, I. H., … Lee, S. J. (2014). Development of replication-competent adenovirus for bladder cancer by controlling adenovirus E1a and E4 gene expression with the survivin promoter. Oncotarget, 5(14), 5615–5623. https://doi.org/10.18632/oncotarget.2151

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

50%

Researcher 2

33%

Professor / Associate Prof. 1

17%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 2

40%

Medicine and Dentistry 1

20%

Chemical Engineering 1

20%

Psychology 1

20%

Save time finding and organizing research with Mendeley

Sign up for free